Confidential rebate reporting and new price regulatory factors of the amended Patented Medicines Regulations declared invalid by the Quebec Court of Appeal

Smart & Biggar
Contact

On February 18, 2022, the Court of Appeal of Quebec released its decision in Merck Canada Inc c Procureur général du Canada (2022 QCCA 240). This is the appeal of the Quebec Superior Court decision declaring price and revenue calculation provisions of the amended Patented Medicines Regulations (“the Regulations”) unconstitutional.

The Court of Appeal varied the judgment of the Quebec Superior Court, and declared ultra vires, invalid and of no effect:

  • New Paragraphs 4(4)(a) and (b) of the amended Regulations, which would have required price and revenue reporting to take into account confidential rebates provided to provincial payers; and
  • New Sections 4.1, 4.2, 4.3 and 4.4 introducing three new price regulatory factors (pharmacoeconomic value, market size, and Gross Domestic Product (GDP) in Canada and GDP per capita in Canada), and the related reporting requirements.

The Quebec Superior Court had found only new Paragraphs 4(4)(a) and (b) unconstitutional.

The Court of Appeal affirmed the lower court judgment declaring valid the remainder of the amended Regulations, including the amended “basket” of reference countries used to establish the price ceiling for a patented medicine (the PMPRB11), and the provisions in the Patent Act relating to PMPRB jurisdiction.

Leave to appeal to the Supreme Court of Canada may be sought.

The amended Regulations will also come under judicial scrutiny in the appeal of the Federal Court decision striking down the price and revenue reporting provisions of the Regulations, which is scheduled to be heard on February 28, 2022.

[View source.]

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Smart & Biggar | Attorney Advertising

Written by:

Smart & Biggar
Contact
more
less

Smart & Biggar on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide